E
Endogenex
DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
About Endogenex
Endogenex is a clinical-stage medical device company, founded in 2017 in partnership with the Mayo Clinic, that is focused on developing therapies for the treatment of Type 2 diabetes. The company is developing the ReCET™ System, which utilizes non-thermal pulsed electric fields in a novel procedure to help patients regain control of their blood glucose levels and reset the body's metabolic system.
The company operates in the medical technology sector and its primary clients are individuals with Type 2 diabetes. Endogenex is a privately held, clinical-stage company that has raised significant funding, including an $88 million Series C financing to complete a pivotal trial of the ReCET™ System. The company is headquartered in Minneapolis, MN.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Minneapolis, United States
- Employees
- 27
- Open positions
- 1
- Dealroom signal
- 76.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Diabetes, Chronic Disease, Spinout, Metabolism, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2026 | $50M | $440M | Arboretum Ventures | ↗ |
| SERIES COther financing | Jun 2024 | $88M | $352M | Hatteras Venture Partners · Sante Ventures · Mayo Clinic · Longitude Capital | ↗ |
Growth signals
Latest recorded traffic for Endogenex is 3.4K monthly website visits, up 3% over the last three months. Endogenex's team grew 8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Hatteras Venture Partners
Sante Ventures
Mayo Clinic
Longitude Capital
Lumira Ventures
Intuitive Ventures
Orlando Health Ventures
Arboretum Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Endogenex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Endogenex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.